- Home
- ANIX vs LUNG Comparison
ANIX vs LUNG Comparison
Compare ANIX & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- LUNG
- Stock Information
- Founded
- ANIX 1982
- LUNG 1995
- Country
- ANIX United States
- LUNG United States
- Employees
- ANIX N/A
- LUNG N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- LUNG Industrial Specialties
- Sector
- ANIX Health Care
- LUNG Health Care
- Exchange
- ANIX Nasdaq
- LUNG Nasdaq
- Market Cap
- ANIX 95.7M
- LUNG 65.6M
- IPO Year
- ANIX 1987
- LUNG 2020
- Fundamental
- Price
- ANIX $2.99
- LUNG $1.71
- Analyst Decision
- ANIX Strong Buy
- LUNG Buy
- Analyst Count
- ANIX 3
- LUNG 7
- Target Price
- ANIX $9.00
- LUNG $7.66
- AVG Volume (30 Days)
- ANIX 71.6K
- LUNG 856.3K
- Earning Date
- ANIX 08-27-2025
- LUNG 10-29-2025
- Dividend Yield
- ANIX N/A
- LUNG N/A
- EPS Growth
- ANIX N/A
- LUNG N/A
- EPS
- ANIX N/A
- LUNG N/A
- Revenue
- ANIX N/A
- LUNG $90,549,000.00
- Revenue This Year
- ANIX N/A
- LUNG $10.30
- Revenue Next Year
- ANIX N/A
- LUNG $14.72
- P/E Ratio
- ANIX N/A
- LUNG N/A
- Revenue Growth
- ANIX N/A
- LUNG 18.24
- 52 Week Low
- ANIX $2.07
- LUNG $1.47
- 52 Week High
- ANIX $4.20
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- ANIX 45.98
- LUNG 41.25
- Support Level
- ANIX $2.93
- LUNG $1.62
- Resistance Level
- ANIX $3.03
- LUNG $1.89
- Average True Range (ATR)
- ANIX 0.10
- LUNG 0.12
- MACD
- ANIX 0.01
- LUNG 0.07
- Stochastic Oscillator
- ANIX 38.89
- LUNG 57.14
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.